Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out.
57% of patients sustained remission of depression, and 64% a robust clinical response, at 18 months following administration of a single 25mg psilocybin dose paired with psychological support
The original Phase 2 trial was completed in 2021 (see results). Now, this 18-month follow-up data is believed to be the longest-term follow-up study of psilocybin therapy with cancer patients ever completed.
See also: Link Between Cancer And Psilocybin: Research On This Palliative Promise
The study assessed a single, …